GlassScriptPhysician profile
Indira Molai
NPI 1992999551
$2,012.05
in general payments reported to CMS, 2019-2025
26 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $97.85 · 2021: $194 · 2022: $29.46 · 2023: $652 · 2024: $491 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $347.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $260.84 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $240.43 | 2020-2025 | Airsupra, Farxiga |
| Amgen INC. | $175.85 | 2020-2024 | Repatha, Otezla |
| Pfizer INC. | $169.59 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.52 | 2023 | Rexulti |
| Novo Nordisk INC | $82.95 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.45 | 2021-2024 | |
| Abbott Laboratories | $73.56 | 2023-2024 | Freestyle Libre 3, Octrode, Freestyle Libre 2 |
| Astellas Pharma US INC | $63.30 | 2019 | |
| Intuitive Surgical, INC. | $46.61 | 2023 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $37.41 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $32.72 | 2024 | Opsumit |
| Exact Sciences Corporation | $30.52 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.84 | 2023 | Belsomra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.72 | 2024 | Cuvitru |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.26 | 2024 | Xifaxan |
| Dexcom, INC. | $22.77 | 2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $22.36 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.78 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $17.23 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $16.23 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.05 | 2019 | |
| Medtronic Vascular, INC. | $15.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Molai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.